3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors inhibit HCV replication in vitro. The combination of sertraline and simvastatin has synergistic antiviral activity in vitro, but there are no prior in vivo studies. Our aims were to prospectively assess the antiviral efficacy and safety of this drug combination in chronic hepatitis C (CHC) patients.
Methods
A total of 15 CHC adults (including 1 control subject) that were treatment-naive or prior partial responders/relapsers to standard-of-care therapy were enrolled at four centres (2 in Singapore and 2 in the US). Patients received simvastatin 40 mg once daily and sertraline 50 mg once daily for 7 days, and then 80 mg once daily and 100 mg once daily, respectively, for another 21 days with a 14-day follow-up.
Results
Of the 15 CHC patients, 13 completed the study. Subjects were mostly Caucasian (8/15), mean age 49.1 ±9 years and the genotype distribution was 1=10, 2=2 and 3=3. No subject discontinued dosing due to adverse events. Mean HCV RNA change from baseline was from -0.005 to -0.236 log10 IU/ml across study intervals. Three subjects had transient >1 log10 HCV RNA declines. No subject achieved >2 log10 HCV RNA decline.
Conclusions
The combination of sertraline and simvastatin is well-tolerated over the short-term, but has no significant antiviral or anti-inflammatory response in CHC patients. This may reflect in vivo differences in synergy between statin and/or selective serotonin reuptake inhibitors and incomplete inhibition of membrane protein prenylation with statin therapy.
References
1.
YeJ., WangC., SumpterR.Jr., BrownM.S., GoldsteinJ.L., GaleM.Jr.. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A2003; 100: 15865–15870.
2.
IkedaM., AbeK., YamadaM., DansakoH., NakaK., KatoN.Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology2006; 44: 117–125.
3.
DelangL., PaeshuyseJ., VliegenI.Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology2009; 50: 6–16.
4.
HarrisonS.A., RossaroL., HuK.Q.Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology2010; 52: 864–874.
5.
BaderT., FaziliJ., MadhounM.Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol2008; 103: 1383–1389.
6.
MilazzoL., MeroniL., GalazziM.Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat2009; 16: 479–484.
7.
LetendreS.L., Marquie-BeckJ., EllisR.J.The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol2007; 2: 120–127.
8.
GlassmanA.H., O'ConnorC.M., CaliffR.M.Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002; 288: 701–709.
9.
BergmanA.J., MurphyG., BurkeJ.Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol2004; 44: 1054–1062.
10.
SchachterM.Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol2005; 19: 117–125.
11.
OwensC.M., MawhinneyC., GrenierJ.M.Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication. Mol Syst Biol2010; 6: 375.
12.
O'LearyJ.G., ChanJ.L., McMahonC.M., ChungR.T.Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology2007; 45: 895–898.
13.
PatelK., JhaveriR., GeorgeJ.Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. J Viral Hepat2011; 18: 331–337.
14.
de DenusS., SpinlerS.A., MillerK., PetersonA.M.Statins and liver toxicity: A meta-analysis. Pharmacotherapy2004; 24: 584–591.
15.
PalinskiW.Immunomodulation: a new role for statins?Nat Med2000; 6: 1311–1312.
16.
MolinaS., CastetV., Fournier-WirthC.The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol2007; 46: 411–419.
17.
PetitJ.M., MinelloA., DuvillardL.Cell surface expression of LDL receptor in chronic hepatitis C: correlation with viral load. Am J Physiol Endocrinol Metab2007; 293: E416–E420.
18.
IkedaM., KatoN.Life style-related diseases of the digestive system: Cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: Suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci2007; 105: 145–150.
19.
SezakiH., SuzukiF., AkutaN.An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology2009; 52: 43–48.
